Amarin Announces Results from Exploratory Phase 2a Study of EN101 in – Businesswire.com
DUBLIN–( BUSINESS WIRE )–Amarin Corporation plc (NASDAQ:AMRN) today announced encouraging top line results from an exploratory Phase 2a multi-centre, dose-ranging, cross-over clinical study of EN101 in patients with myasthenia gravis, a chronic
Amarin Announces Results from Exploratory Phase 2a Study of EN101 in – Businesswire.com
June 13, 2009 By Leave a Comment
Speak Your Mind
You must be logged in to post a comment.

